Table 2.
Patient demographics and characteristics
| Characteristic | Number |
|---|---|
| Number of patients | 16 |
| Total number of courses | 42 |
| Number of courses per patient | |
| Median | 3 |
| Range | 1–8 |
| Patients receiving ≥2 cycles of therapy | 9 |
| Sex | |
| Male | 5 |
| Female | 11 |
| Age | |
| Median (in years) | 54 |
| Range (in years) | 41–67 |
| ECOG performance status | |
| 0 | 4 |
| 1 | 11 |
| 2 | 1 |
| Previous treatment | |
| Mean prior chemotherapy regimens | 2 |
| Range of prior chemotherapy regimens | 0–6 |
| Fewer than three prior chemotherapy regimens | 8 |
| Three or greater prior chemotherapy regimens | 3 |
| Prior investigational/ targeted therapy/clinical triala | 6 |
| Prior immunotherapy | 3 |
| No prior chemotherapy or radiation therapy | 1 |
| Prior radiotherapy | 9 |
| Tumor type | |
| Melanoma | 5 |
| Ovarian | 3 |
| Breast cancer | 3 |
| Otherb | 6 |
Abbreviation: ECOG Eastern Cooperative Oncology Group
a
Includes interferon, IL-2 and vaccines, autologous stem cell transplantation, isolated hepatic perfusion and clinical trials with novel agents
b
Other tumor types include one of each including of cystic adenocarcinoma of the tongue, colon cancer, thymoma, gastric cancer, fallopian tube adenocarcinoma, and squamous cell carcinoma of the head and neck